Good
Mostly Aligned
Patient Risk:
Low
Summary
Most mechanism, dosing frequency, and general efficacy statements align with the provided label excerpts. However, the label excerpts provided do not support claims about HDL increase and do not address the patent/biosimilar statements; additionally, the “high cholesterol” framing is incomplete because the label’s key indications include CV event risk reduction and specific hypercholesterolemia/HeFH/HoFH populations.
Category Scores
Accurate Statements
Repatha (evolocumab) is a monoclonal antibody that targets PCSK9.
12 DESCRIPTION/11 DESCRIPTION: “Evolocumab is a human monoclonal … directed against … PCSK9.”; 12.1 Mechanism of Action: “Evolocumab is a human monoclonal IgG2 directed against … PCSK9.”
PCSK9 is involved in cholesterol production in the liver.
12.1 Mechanism of Action: PCSK9 “binds to the low-density lipoprotein receptor (LDLR) … on the surface of hepatocytes … within the liver.”
By blocking PCSK9, Repatha helps reduce the amount of LDL cholesterol in the blood.
12.1 Mechanism of Action: inhibiting PCSK9-LDLR binding “increases the number of LDLRs available to clear LDL … thereby lowering LDL-C levels.”
Repatha is an injectable prescription medicine administered every 2 weeks or monthly.
2.1 Recommended Dosage: “140 mg every 2 weeks OR 420 mg once monthly administered subcutaneously.”
Clinical trials have shown that Repatha can effectively lower LDL cholesterol in most patients with high cholesterol.
14 Clinical Studies: multiple trials show large negative % change in LDL-C (e.g., LAPLACE-2, MENDEL-2, DESCARTES) and mean LDL-C reductions.
Patient responses to Repatha can vary.
14 Clinical Studies: “the LDL-lowering effect of REPATHA may be measured as early as 4 weeks…;” and specific note: “LDL-C can vary during the dosing interval in some patients; recommend measuring… just prior to the next scheduled dose.”
Studies have demonstrated that Repatha can significantly reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with high cholesterol.
14 Clinical Studies (FOURIER): “REPATHA significantly reduced the risk for the primary composite endpoint…” components include “myocardial infarction” and “stroke.”
Self-administration of Repatha is possible with guidance of a healthcare professional.
17 Patient Counseling Information: provides administration technique guidance for SureClick autoinjector/syringe and how to use devices; indicates patient/caregiver guidance (implies potential self-administration with proper instruction).
Common side effects of Repatha may include injection site reactions.
6 Adverse Reactions: Table 1 includes “Injection site reactions … 5.7%” in REPATHA-treated vs placebo 5.0%; and local injection site reactions described.
Unsupported Statements
Repatha has been shown to increase high-density lipoprotein (HDL) cholesterol.
The provided label excerpts do not state that REPATHA increases HDL-C.
Common side effects of Repatha may include muscle and bone pain.
The provided excerpts include “myalgia” and “musculoskeletal pain” but do not specifically support the broader phrasing “muscle and bone pain.” (Myalgia/musculoskeletal pain are present; “bone pain” specifically is not shown in the excerpts.)
Common side effects of Repatha may include flu-like symptoms.
The provided excerpts list influenza and upper respiratory tract infection, but do not contain the term “flu-like symptoms.”
Repatha's patent is set to expire in 2028.
No patent expiration information is present in the provided label excerpts.
After Repatha's patent expires in 2028, biosimilar versions may enter the market.
No patent/biosimilar market entry statements are present in the provided label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
The AI claim “used to treat high cholesterol” omits that the label indication includes reducing risk of major adverse cardiovascular events in adults at increased risk (not just LDL lowering).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No label-provided contraindications/warnings/drug-interaction statements were included in the AI claims. Main potential issues are informational accuracy (HDL increase, side-effect characterization) and omission of key indication scope. Patent/biosimilar statements are unsupported but not a direct dosing/safety issue.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported claims: HDL increase; and unsupported non-label patent/biosimilar statements. Side-effect statements are partially supported but phrased more broadly than the provided adverse reaction excerpts.
Suggested Improvement
Limit claims to label-supported items from the provided excerpts: (1) avoid stating HDL increase; (2) remove patent/biosimilar timing statements; (3) rephrase side effects to match label terms (e.g., injection site reactions, myalgia/musculoskeletal pain, influenza as listed) rather than “bone pain” or “flu-like symptoms.” Also include the label’s cardiovascular event risk-reduction indication rather than focusing only on cholesterol.